The X-linked Tumor Suppressor TSPX Downregulates Cancer-drivers/oncogenes in Prostate Cancer in a C-terminal Acidic Domain Dependent Manner

Overview

Journal Oncotarget

Specialty Oncology

Date 2019 Mar 14

PMID 30863497

Citations 6

Authors

Tatsuo Kido

Yunmin Li

Yuichiro Tanaka

Rajvir Dahiya

Yun-Fai Chris Lau

Affiliations

Soon will be listed here.

Abstract

TSPX is a tumor suppressor gene located at Xp11.22, a prostate cancer susceptibility locus. It is ubiquitously expressed in most tissues but frequently downregulated in various cancers, including lung, brain, liver and prostate cancers. The C-terminal acidic domain (CAD) of TSPX is crucial for the tumor suppressor functions, such as inhibition of cyclin B/CDK1 phosphorylation and androgen receptor transactivation. Currently, the exact role of the TSPX CAD in transcriptional regulation of downstream genes is still uncertain. Using different variants of TSPX, we showed that overexpression of either TSPX, that harbors a CAD, or a CAD-truncated variant (TSPX[∆C]) drastically retarded cell proliferation in a prostate cancer cell line LNCaP, but cell death was induced only by overexpression of TSPX. Transcriptome analyses showed that TSPX or TSPX[∆C] overexpression downregulated multiple cancer-drivers/oncogenes, including MYC and MYB, in a CAD-dependent manner and upregulated various tumor suppressors in a CAD-independent manner. Datamining of transcriptomes of prostate cancer specimens in the Cancer Genome Atlas (TCGA) dataset confirmed the negative correlation between the expression level of TSPX and those of MYC and MYB in clinical prostate cancer, thereby supporting the hypothesis that the CAD of TSPX plays an important role in suppression of cancer-drivers/oncogenes in prostatic oncogenesis.

Citing Articles

The X-Linked Tumor Suppressor TSPX Regulates Genes Involved in the EGFR Signaling Pathway and Cell Viability to Suppress Lung Adenocarcinoma.

Kido T, Kong H, Lau Y Genes (Basel). 2025; 16(1).

PMID: 39858622 PMC: 11764513. DOI: 10.3390/genes16010075.

Oncogenes and tumor suppressor genes: functions and roles in cancers.

Dakal T, Dhabhai B, Pant A, Moar K, Chaudhary K, Yadav V MedComm (2020). 2024; 5(6):e582.

PMID: 38827026 PMC: 11141506. DOI: 10.1002/mco2.582.

AAV9-Tspyl2 gene therapy retards bleomycin-induced pulmonary fibrosis by modulating downstream TGF-β signaling in mice.

Zhang S, Tong X, Liu S, Huang J, Zhang L, Zhang T Cell Death Dis. 2023; 14(6):389.

PMID: 37391440 PMC: 10313802. DOI: 10.1038/s41419-023-05889-8.

Screening key miRNAs and genes in prostate cancer by microarray analysis.

Wu J, Li X, Luo F, Yan J, Yang K Transl Cancer Res. 2022; 9(2):856-868.

PMID: 35117431 PMC: 8799076. DOI: 10.21037/tcr.2019.12.30.

The Role of Cell Division Autoantigen 1 (CDA1) in Renal Fibrosis of Diabetic Nephropathy.

Chen L, Wu J, Hu B, Liu C, Wang H Biomed Res Int. 2021; 2021:6651075.

PMID: 33997036 PMC: 8102118. DOI: 10.1155/2021/6651075.

References

Li K, Chen M, Li L, Lu M, Shao C, Su Z . The predictive value of semaphorins 3 expression in biopsies for biochemical recurrence of patients with low- and intermediate-risk prostate cancer. Neoplasma. 2013; 60(6):683-9. DOI: 10.4149/neo_2013_087. View

Yu J, Gu X, Yi S . Ingenuity Pathway Analysis of Gene Expression Profiles in Distal Nerve Stump following Nerve Injury: Insights into Wallerian Degeneration. Front Cell Neurosci. 2016; 10:274. PMC: 5138191. DOI: 10.3389/fncel.2016.00274. View

Lobry C, Oh P, Mansour M, Look A, Aifantis I . Notch signaling: switching an oncogene to a tumor suppressor. Blood. 2014; 123(16):2451-9. PMC: 3990910. DOI: 10.1182/blood-2013-08-355818. View

Marshall Graves J . Sex chromosome specialization and degeneration in mammals. Cell. 2006; 124(5):901-14. DOI: 10.1016/j.cell.2006.02.024. View

Li W, Gu M . NUDT11 rs5945572 polymorphism and prostate cancer risk: a meta-analysis. Int J Clin Exp Med. 2015; 8(3):3474-81. PMC: 4443072. View

Boyd L, Mao X, Lu Y . The complexity of prostate cancer: genomic alterations and heterogeneity. Nat Rev Urol. 2012; 9(11):652-64. DOI: 10.1038/nrurol.2012.185. View

Srivastava S, Bhardwaj A, Singh S, Arora S, McClellan S, Grizzle W . Myb overexpression overrides androgen depletion-induced cell cycle arrest and apoptosis in prostate cancer cells, and confers aggressive malignant traits: potential role in castration resistance. Carcinogenesis. 2012; 33(6):1149-57. PMC: 3514863. DOI: 10.1093/carcin/bgs134. View

Nesbit C, Tersak J, Prochownik E . MYC oncogenes and human neoplastic disease. Oncogene. 1999; 18(19):3004-16. DOI: 10.1038/sj.onc.1202746. View

Liao Y, Smyth G, Shi W . featureCounts: an efficient general purpose program for assigning sequence reads to genomic features. Bioinformatics. 2013; 30(7):923-30. DOI: 10.1093/bioinformatics/btt656. View

10.

Buganim Y, Itskovich E, Hu Y, Cheng A, Ganz K, Sarkar S . Direct reprogramming of fibroblasts into embryonic Sertoli-like cells by defined factors. Cell Stem Cell. 2012; 11(3):373-86. PMC: 3438668. DOI: 10.1016/j.stem.2012.07.019. View

11.

Mao B, Zhang Z, Wang G . BTG2: a rising star of tumor suppressors (review). Int J Oncol. 2014; 46(2):459-64. DOI: 10.3892/ijo.2014.2765. View

12.

Jalava S, Urbanucci A, Latonen L, Waltering K, Sahu B, Janne O . Androgen-regulated miR-32 targets BTG2 and is overexpressed in castration-resistant prostate cancer. Oncogene. 2012; 31(41):4460-71. DOI: 10.1038/onc.2011.624. View

13.

Li W, Wang L, Katoh H, Liu R, Zheng P, Liu Y . Identification of a tumor suppressor relay between the FOXP3 and the Hippo pathways in breast and prostate cancers. Cancer Res. 2011; 71(6):2162-71. PMC: 3070402. DOI: 10.1158/0008-5472.CAN-10-3268. View

14.

Meyer N, Penn L . Reflecting on 25 years with MYC. Nat Rev Cancer. 2008; 8(12):976-90. DOI: 10.1038/nrc2231. View

15.

Boutros P, Fraser M, Harding N, De Borja R, Trudel D, Lalonde E . Spatial genomic heterogeneity within localized, multifocal prostate cancer. Nat Genet. 2015; 47(7):736-45. DOI: 10.1038/ng.3315. View

16.

Rebello R, Pearson R, Hannan R, Furic L . Therapeutic Approaches Targeting MYC-Driven Prostate Cancer. Genes (Basel). 2017; 8(2). PMC: 5333060. DOI: 10.3390/genes8020071. View

17.

Mendez-Catala C, Gretton S, Vostrov A, Pugacheva E, Farrar D, Ito Y . A novel mechanism for CTCF in the epigenetic regulation of Bax in breast cancer cells. Neoplasia. 2013; 15(8):898-912. PMC: 3730042. DOI: 10.1593/neo.121948. View

18.

Lever J, Zhao E, Grewal J, Jones M, Jones S . CancerMine: a literature-mined resource for drivers, oncogenes and tumor suppressors in cancer. Nat Methods. 2019; 16(6):505-507. DOI: 10.1038/s41592-019-0422-y. View

19.

Wang L, Liu R, Li W, Chen C, Katoh H, Chen G . Somatic single hits inactivate the X-linked tumor suppressor FOXP3 in the prostate. Cancer Cell. 2009; 16(4):336-46. PMC: 2758294. DOI: 10.1016/j.ccr.2009.08.016. View

20.

Camp N, Farnham J, Wong J, Christensen G, Thomas A, Cannon-Albright L . Replication of the 10q11 and Xp11 prostate cancer risk variants: results from a Utah pedigree-based study. Cancer Epidemiol Biomarkers Prev. 2009; 18(4):1290-4. PMC: 2697376. DOI: 10.1158/1055-9965.EPI-08-0327. View